Modality
Gene Editing
MOA
BCMA ADC
Target
C5
Pathway
Sphingolipid
Bladder Ca
Development Pipeline
Preclinical
Aug 2024
→ May 2031
PreclinicalCurrent
NCT05993676
1,307 pts·Bladder Ca
2024-08→2031-05·Not yet recruiting
1,307 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-135.1y awayInterim· Bladder Ca
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Not yet…
Catalysts
Interim
2031-05-13 · 5.1y away
Bladder Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05993676 | Preclinical | Bladder Ca | Not yet recr... | 1307 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| HAL-1232 | Halozyme | Approved | C5 |